



Platelet-Rich Plasma (PRP) Effect on Androgenetic Alopecia and Female Pattern Hair Loss

Elham Behrangi¹, Abbas Zamanian¹, Gholamhossein Ghaffarpour¹, Maryam Hashemi Orimi^{1*}, Amir Heydarian¹ and Zahra Azizian¹

¹Dermatology Department, Iran University of Medical Sciences, Tehran, Iran

*Corresponding author: Dermatology Department, Iran University of Medical Sciences, Tehran, Iran. Email: drhashemi91@gmail.com

Received 2018 December 19; Revised 2019 April 06; Accepted 2019 December 01.

Abstract

Background: Androgenetic Alopecia is a chronic form of hair loss affecting both male and female; 20% of Caucasian men and 40% of women, respectively. Plasma Rich Platelet (PRP) is a blood plasma with higher platelet concentration. It seems that in androgenetic alopecia, growth factors have an important role in transformation and development of terminal hair to vellus hair. The growth factors in PRP can affect this process.

Methods: This was a case control study that was performed on 120 patients with grade II and III androgenetic alopecia, based on the Hamilton-Norwood classification system and grade 1 to 5 female pattern alopecia. Participants were randomly divided into two groups of 30 patients. The first group was treated with Finasteride and the second underwent PRP treatment; with a group of 60 participants who received placebo. Follow-up was performed using macroscopic photography and Pull test base line, monthly for three months, and finally three months after PRP-treatment for patients who received PRP.

Results: A total number of 120 participants enrolled in this study; 28 patients in the PRP group, 26 patients in the Finasteride group and 60 patients in the control group. The results of one month follow up showed that hair growth and hair loss reduction were not significantly improved in the PRP group compared to the Finasteride and control groups ($P \geq 0.05$). Significant differences were observed in results of progression of hair growth and reduction of hair loss between groups after three and six months (P value: 00.)

Conclusions: PRP-treatment is a novel therapeutic approach. The effective results of PRP-treatment might be due to this eagerness. Furthermore, the time duration of this procedure is short, which is an important factor for the patients since most of the participants are young men who do not tend to undergo long-time treatments, such as Finasteride consumption and Minoxidil application.

Keywords: Androgenetic Alopecia, Plasma-Rich Platelet, Hair Loss

1. Background

Androgenetic Alopecia (AGA) is a chronic hair loss affecting both male and female, 20% of Caucasian men and 40% of women, respectively (1, 2). There are only two FDA approved products available for AGA treatment, Minoxidil and Finasteride. Unfortunately, these products are not compliant and satisfactory for the patients.

Plasma-Rich Platelet (PRP), as a new treatment approach, has been recently attracting more attention. PRP is blood plasma with higher concentration of the platelet (1). The therapeutic application of PRP, which has been shown to be mediated by growth factors, was first proposed in the wound healing process (3). Thereafter, PRP was suggested to be used as a pre-treatment technique in hair transplantation procedure (1). Recent studies have proposed PRP as a worthy treatment in androgenetic alopecia (1, 4-6).

It seems that growth factors play an important role in the transformation and development of terminal hair to vellus hair in androgenetic alopecia (4). PRP induces its effect on this process by vascular endothelial growth factor (VEGF) (3). Other growth factors that play a crucial role in androgenetic alopecia are fibroblast growth factor 7 (FGF-7), B-Catein signal related kinase (ERK), and AKT signaling (3).

2. Methods

This study was approved by the Ethics Committee of Iran University. This was a case control study, which was conducted during January 2015 to June 2017 on 120 male patients with a male pattern grade of II and III androgenetic alopecia, based on the Hamilton-Norwood classifica-

tion system and female pattern (the Sinclair scale for female pattern hair loss, stage 1-5) (2).

Participants were randomly divided into two groups of 30 patients; the first group was treated with Finastride and the second group underwent PRP treatment. Furthermore, 60 participants received placebo as a control group. All the patients were informed formally and signed a consent form prior to enrollment in the study (IRCT2014062918210N2R1/18210).

Placebo consisting of normal saline was applied every night. The exclusion criteria included any application of topical materials on the scalp for treatment of hair loss or other diseases at least six months before the initiation of this study, any medical conditions, including malignancy, hematologic disease, and rheumatologic disease. The age range of the participants was 20 to 40 years, all of them being male. Patients who smoked were asked to stop smoking one week prior to their PRP procedure.

2.1. PRP Technique

PRP was performed in three sessions every month. First, 20 cc blood was drawn from each patient using a standard kit. Blood samples were centrifuged at 3400 rpm twice for three minutes. Approximately, 3 - 5 cc PRP was extracted from each sample.

Activation process was induced using Calcium Gluconate in a 1.9 ratio. Finally, PRP was injected in six distinctive areas of the affected scalp after frontal block anesthesia, by a 30-gauge needle, which was used for Mesotherapy. The success rate of the procedure was graded according to the patient's satisfaction, Pull test examination, and blinded physician assessment by photography to 3 scores (no improvement, minimal, significant improvement). Follow-up was performed using the macroscopic photography of Vertex and occipital region and Pull test along this study at the base line, monthly for 3 months, and finally 3 months after PRP-treatment for patients who received PRP.

Images of the treated area were acquired at each session using the same camera and two independent physicians evaluated the images (Figure 1). Statistical analyses were performed using SPSS version 21. Chi-square, *t*-test, and Mann-Whitney U test were used for statistical analyses. P value of less than 0.05 was considered significant.

3. Results

A total number of 120 participants enrolled in this study; 28 patients in the PRP group, 26 patients in the Finastride group and 60 patients in the control group. Totally, eight patients, two of the PRP group and six of Fi-



Figure 1. Patient A before PRP treatment (A) and after PRP treatment (B)

nastride groups, discontinued treatment. demographic features of patients are presented (Table 1).

The results of one month follow up showed that hair growth and hair loss reduction were not significantly improved in the PRP group compared to the Finastride and control groups ($P \geq 0.05$) (Table 2).

Interestingly, the progression of hair growth and hair loss reduction had no correlation with age, grade, and type of alopecia; results were similar in patients with androgenetic alopecia and female pattern hair loss (P value > 0.05).

Table 1. Demographic Data of Patients

| | PRP Group | Finasteride | Control |
|-----------------------|------------|-------------|-------------|
| Age | 27.6 | 29.1 | 28.9 |
| Alopecia grade | | | |
| II | 1 (3.6%) | | 19 (31.75%) |
| III | 2 (7.1%) | 13 (50%) | 15 (25%) |
| IIIa | 0 | 1 (3.8%) | 0 |
| IIIvertex | 16 (57.1%) | 4 (15.4%) | |
| FPL | | | |
| III | 1 (3.6%) | 4 (15.4%) | 11 (9.6%) |
| IV | 5 (17.9%) | 0 | 10 (8.8%) |
| V | 3 (2.7%) | 4 (15.4%) | 12 (10.5%) |

Table 2. Improvement Grade Between Groups After 1 Month.

| | PRP Group | Finasteride | Control | P Value |
|-------------------------|------------|-------------|------------|---------|
| No improvement | 14 (50%) | 17 (65.4%) | 47 (68.4%) | |
| Moderate improvement | 13 (46.4%) | 9 (34.6%) | 13 (21.7%) | 0.06 |
| Significant improvement | 1 (3.6%) | 0 | 0 | |

Significant differences were observed in results of progression of hair growth and reduction of hair loss between groups after three and six months (P value: 0.0) (Tables 3 and 4, and Figure 1).

4. Discussion

Findings of this study are comparable to other studies. These results were consistent to those presented by Lee et al. (7), and Gkini et al. (1). They showed that PRP can reduce hair loss and increase hair volume.

In another study, Khatu et al., performed PRP-treatment four times every two weeks and have shown patients' satisfaction between the first and fourth sessions. This result was unlike our finding where no improvement was observed in our study one month after the last treatment session; only three months after the last treatment session significant hair loss reduction and hair growth were observed (4).

Most of the patients who participated in this study experienced hair loss along the procedure, which can be considered as a telogen effluvium effect of injection procedure. These findings are not consistent with Utter's study that mentioned no side effect in patients undergoing PRP procedure (8).

The present study is less valid compared to the double-blind study conducted by Gentile et al., that investigated the efficacy of PRP on hair loss. This is due to the fact

that the participants in the current study were concerned about the modality of their treatment, which could encourage them to continue PRP procedure more than consuming Finasteride due to their concept of PRP as a more efficient treatment (9).

This study investigated both androgenetic alopecia and female pattern hair loss in male patients, which is a prominent point of the present study because a few studies have examined the effect of PRP on female pattern alopecia in males. Furthermore, findings of this study are consistent with those presented by Lee et al., who found that PRP treatment has a positive effect on this type of Alopecia (7).

4.1. Conclusions

This study showed that PRP has a beneficial effect not only on hair loss reduction but also on hair re-growth process. Therefore, PRP-treatment is a new therapeutic approach that has received highly favorable reviews by patients. The treatment sessions were not discontinued by the patients. The positive results of PRP-treatment may be due to the patients' eagerness. Moreover, the duration of this procedure is short, which is an important factor for the patients since most of the participants were young men who do not tend to undergo long-time treatments, such as Finasteride consumption and Minoxidil application. Further in-depth studies are required in this field, for instance Trichoscopy to reach precise PRP findings.

Table 3. Improvement Grade Between Groups After 3 Months

| | PRP Group | Finasteride | Control | P Value |
|-------------------------|------------|-------------|-----------|---------|
| No improvement | 3 (10.7%) | 17 (65.4%) | 60 (100%) | 0.0 |
| Moderate improvement | 10 (35.7%) | 8 (30.8%) | 0 | |
| Significant improvement | 15 (53.6%) | 1 (3.8%) | 0 | |

Table 4. Improvement Grade Between Groups After 6 Months

| | PRP Group | Finasteride | Control | P Value |
|-------------------------|------------|-------------|------------|---------|
| No improvement | 3 (10.7%) | 15 (57.7%) | 34 (97.1%) | 0.0 |
| Moderate improvement | 10 (35.7%) | 9 (34.6%) | 1 (2.9%) | |
| Significant improvement | 15 (53.6%) | 2 (7.7%) | 0 | |

Footnotes

Authors' Contribution: Abbas Zamanian: study design, Elham Behrangi: data collection, Gholamhossein Ghafarfarpour: data collection, Amir Heydarian: data collection, Zahra Azizian: writing and editing, Maryam Hashemi Orimi: writing and editing

Conflict of Interests: None.

Ethical Approval: This study was approved by the Ethics Committee of Iran University (IRCT2014062918210N2R1/18210).

Funding/Support: None.

Patient Consent: All the patients were informed formally and signed a consent form prior to enrollment in the study.

References

- Gkini MA, Kouskoukis AE, Tripsianis G, Rigopoulos D, Kouskoukis K. Study of platelet-rich plasma injections in the treatment of androgenic alopecia through an one-year period. *J Cutan Aesthet Surg.* 2014;7(4):213-9. doi: [10.4103/0974-2077.150743](https://doi.org/10.4103/0974-2077.150743). [PubMed: [25722600](https://pubmed.ncbi.nlm.nih.gov/25722600/)]. [PubMed Central: [PMC4338465](https://pubmed.ncbi.nlm.nih.gov/PMC4338465/)].
- Bologna J, Jorizzo JL, Schaffer JV. *Dermatology*. 3rd ed. Philadelphia: Elsevier Saunders; 2012.
- Cervelli V, Garcovich S, Bielli A, Cervelli G, Curcio BC, Scioli MG, et al. The effect of autologous activated platelet rich plasma (AA-PRP) injection on pattern hair loss: clinical and histomorphometric evaluation. *Biomed Res Int.* 2014;2014:760709. doi: [10.1155/2014/760709](https://doi.org/10.1155/2014/760709). [PubMed: [24883322](https://pubmed.ncbi.nlm.nih.gov/24883322/)]. [PubMed Central: [PMC4032742](https://pubmed.ncbi.nlm.nih.gov/PMC4032742/)].
- Khatu SS, More YE, Gokhale NR, Chavhan DC, Bendsure N. Platelet-rich plasma in androgenic alopecia: Myth or an effective tool. *J Cutan Aesthet Surg.* 2014;7(2):107-10. doi: [10.4103/0974-2077.138352](https://doi.org/10.4103/0974-2077.138352). [PubMed: [25136212](https://pubmed.ncbi.nlm.nih.gov/25136212/)]. [PubMed Central: [PMC4134641](https://pubmed.ncbi.nlm.nih.gov/PMC4134641/)].
- Lynch MD, Bashir S. Applications of platelet-rich plasma in dermatology: A critical appraisal of the literature. *J Dermatolog Treat.* 2016;27(3):285-9. doi: [10.3109/09546634.2015.1094178](https://doi.org/10.3109/09546634.2015.1094178). [PubMed: [26466811](https://pubmed.ncbi.nlm.nih.gov/26466811/)].
- Leo MS, Kumar AS, Kirit R, Konathan R, Sivamani RK. Systematic review of the use of platelet-rich plasma in aesthetic dermatology. *J Cosmet Dermatol.* 2015;14(4):315-23. doi: [10.1111/jocd.12167](https://doi.org/10.1111/jocd.12167). [PubMed: [26205133](https://pubmed.ncbi.nlm.nih.gov/26205133/)].
- Lee SH, Zheng Z, Kang JS, Kim DY, Oh SH, Cho SB. Therapeutic efficacy of autologous platelet-rich plasma and polydeoxyribonucleotide on female pattern hair loss. *Wound Repair Regen.* 2015;23(1):30-6. doi: [10.1111/wrr.12250](https://doi.org/10.1111/wrr.12250). [PubMed: [25524027](https://pubmed.ncbi.nlm.nih.gov/25524027/)].
- Singh S. Role of platelet-rich plasma in chronic alopecia areata: Our centre experience. *Indian J Plast Surg.* 2015;48(1):57-9. doi: [10.4103/0970-0358.155271](https://doi.org/10.4103/0970-0358.155271). [PubMed: [25991888](https://pubmed.ncbi.nlm.nih.gov/25991888/)]. [PubMed Central: [PMC4413492](https://pubmed.ncbi.nlm.nih.gov/PMC4413492/)].
- Gentile P, Garcovich S, Bielli A, Scioli MG, Orlandi A, Cervelli V. The effect of platelet-rich plasma in hair regrowth: A randomized placebo-controlled trial. *Stem Cells Transl Med.* 2015;4(11):1317-23. doi: [10.5966/sctm.2015-0107](https://doi.org/10.5966/sctm.2015-0107). [PubMed: [26400925](https://pubmed.ncbi.nlm.nih.gov/26400925/)]. [PubMed Central: [PMC4622412](https://pubmed.ncbi.nlm.nih.gov/PMC4622412/)].